Personalized Tamoxifen: A Step Closer But Miles To... [Clin Cancer Res. 2010] - PubMed result

Clin Cancer Res. 2010 Jul 22. [Epub ahead of print]

Personalized Tamoxifen: A Step Closer But Miles To Go.
Bardia A, Stearns V.

Hematology/Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine.

Abstract
Genetic variants in CYP2D6 lead to reduced conversion of tamoxifen to the active metabolite endoxifen. However, the role of CYP2D6 genotype in predicting tamoxifen-associated outcomes remains controversial. Accurate assignment of CYP2D6 genotype in archival tissues is crucial for future studies attempting to determine risk prediction of outcomes in tamoxifen-treated individuals.

PMID: 20651057 [PubMed - as supplied by publisher]
Personalized Tamoxifen: A Step Closer But Miles To... [Clin Cancer Res. 2010] - PubMed result